IMR Press / RCM / Volume 19 / Issue 3 / DOI: 10.31083/j.rcm.2018.03.3185
Open Access Review
Baroreflex stimulation for treating resistant hypertension: ready for the prime-time?
Show Less
1 CNR-Institute of Clinical Physiology, Reggio Calabria, 89124, Italy
2 Renal Unit, Department of Health Sciences, "Magna Graecia" University, Catanzaro, 98100, Italy

*Correspondence: (Davide Bolignano)

Rev. Cardiovasc. Med. 2018, 19(3), 89–95;
Published: 30 September 2018
The search of alternative methods for improving clinical management and outcomes of individuals affected by resistant hypertension has become a true health priority. In this review, we aimed at providing a timely overview and evidence synthesis on baroreflex activation therapy (BAT) and endovascular baroreflex amplification (EBA), two device-based therapies which rely on the principle of lowering blood pressure by stimulating the carotid baroreflex to decrease the sympathetic and enhance the parasympathetic activity. In resistant forms of arterial hypertension, accruing evidence has confirmed the capacity of these techniques to improve blood pressure control and to reduce the amount of anti-hypertensive therapy at cost of few side effects. Future results from ongoing randomized sham-controlled trials are eagerly awaited to best define the efficacy, safety and durability of effects in the long term before such an invasive approach may be considered as a suitable option in daily clinical practice.
Resistant hypertension
baroreflex activation therapy
endovascular baroreflex amplification
Back to top